Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Liraglutide-Generic is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with type 2 diabetes mellitus.
Lead Product(s): Liraglutide
Therapeutic Area: Endocrinology Product Name: Liraglutide-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Zentiva
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2024
Details:
The collaboration aims to support the Biocon for the commercialization of ACTIBLOK IPR 25 (metoprolol succinate). It is an approved product indicated for the treatment of hypertension and angina pectoris.
Lead Product(s): Metoprolol Succinate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACTIBLOK IPR 25
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eris Pharmaceuticals
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 13, 2024
Details:
The partnership seeks to enhance the commercialization efforts of Ogivri (trastuzumab), an FDA-approved biosimilar product utilized in the treatment of patients diagnosed with breast cancer or metastatic stomach cancer.
Lead Product(s): Trastuzumab
Therapeutic Area: Oncology Product Name: Ogivri
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 10, 2024
Details:
Through the divestment, Eris gains Biocon's Dermatology and Nephrology branded formulations business units in India that mostly comprised of its legacy small molecules’ brands, including Advacan (everolimus), an anti-cancer medicine.
Lead Product(s): Everolimus
Therapeutic Area: Oncology Product Name: Advacan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eris Lifesciences
Deal Size: $43.8 million Upfront Cash: Undisclosed
Deal Type: Divestment November 09, 2023
Details:
Under the terms of this agreement, Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market.
Lead Product(s): Liraglutide
Therapeutic Area: Endocrinology Product Name: Saxenda-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Juno Pharmaceuticals Pty Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 06, 2023
Details:
YESAFILI (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular (wet) age-related macular degeneration (AMD), various types of macular edema and diabetic retinopathy.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: Yesafili
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
HULIO (adalimumab-fkjp) is a biosimilar product of HUMIRA®, formulated for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritisetc. The drug bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface.
Lead Product(s): Adalimumab-fkjp
Therapeutic Area: Immunology Product Name: Hulio
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 03, 2023
Details:
Abevmy (bevacizumab-maly) acts by selectively binding circulating VEGF, thereby inhibiting the binding of VEGF to its cell surface receptors. This inhibition leads to a reduction in microvascular growth of tumor blood vessels and thus limits the blood supply to tumor tissues.
Lead Product(s): Bevacizumab-maly
Therapeutic Area: Oncology Product Name: Abevmy
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Biocon
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2023
Details:
Humulin® R U-100 is a polypeptide hormone structurally identical to human insulin synthesized through rDNA technology in a special non-disease-producing laboratory strain of Escherichia coli bacteria.
Lead Product(s): Recombinant Insulin
Therapeutic Area: Endocrinology Product Name: Insulin-R
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2023
Details:
EQ001 (Itolizumab), is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway, which can drive several immuno-inflammatory diseases. This unique molecule holds the potential for multiple high-value indications.
Lead Product(s): Itolizumab
Therapeutic Area: Gastroenterology Product Name: EQ001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022